Genmab CEO: Tivdak launch has provided important experience for future treatments
The launch of Tivdak in the US, which is currently taking place, is providing Genmab with important experiences ahead of the launch of epcoritamab with partner Abbvie later this year, says company CEO Jan van de Winkel.
by andreas lønstrup, translated by catherine brett
Tivdak, which was approved as a cervical cancer treatment in the US last year, is the first drug that Danish biotech company Genmab has chosen to sell and market itself.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Janssen submits Genmab-developed drug for EMA approval
For subscribers
